Subgroup analysis after propensity score-matched analysis
| Variable | Cumulative incidence of cancer-specific death | P1 value | P2 value | ||
| 3 years | 5 years | 7 years | Cancer-specific death | Other reasons | |
| Overall | 0.913 | 0.017 | |||
| ICC | 57.75% | 72.45% | 80.11% | ||
| ECC | 60.65% | 73.31% | 75.27% | ||
| Age | |||||
| ≤60 | 0.301 | 0.015 | |||
| ICC | 51.74% | 61.29% | 69.03% | ||
| ECC | 42.40% | 57.01% | 57.01% | ||
| >60 | 0.384 | 0.292 | |||
| ICC | 60.26% | 76.76% | 85.05% | ||
| ECC | 68.39% | 80.21% | 83.79% | ||
| Sex | |||||
| Female | 0.370 | 0.027 | |||
| ICC | 53.02% | 73.50% | 82.61% | ||
| ECC | 58.26% | 77.39% | 77.39% | ||
| Male | 0.618 | 0.168 | |||
| ICC | 60.81% | 71.56% | 77.73% | ||
| ECC | 61.92% | 70.54% | 73.34% | ||
| Race | |||||
| Black | 0.096 | NA | |||
| ICC | 0% | NA | NA | ||
| ECC | NA | NA | NA | ||
| White | 0.841 | 0.062 | |||
| ICC | 60.88% | 73.76% | 81.83% | ||
| ECC | 62.16% | 71.96% | 74.11% | ||
| Others | 0.984 | 0.073 | |||
| ICC | 47.45% | 70.44% | 70.44% | ||
| ECC | 42.88% | NA | NA | ||
| AJCC clinical stage | |||||
| Grade I | 0.901 | 0.105 | |||
| ICC | 48.48% | 64.49% | 82.36% | ||
| ECC | 53.05% | 66.10% | 69.01% | ||
| Grade II | 0.364 | NA | |||
| ICC | 44.44% | NA | NA | ||
| ECC | 72.66% | NA | NA | ||
| Grade III | 0.628 | 0.442 | |||
| ICC | 67.88% | 82.04% | 82.04% | ||
| ECC | 65.35% | 79.78% | NA | ||
| Grade IV | 0.927 | 0.450 | |||
| ICC | 89.20% | NA | NA | ||
| ECC | 87.44% | NA | NA | ||
| Unknown | 0.721 | 0.237 | |||
| ICC | 53.13% | 53.13% | NA | ||
| ECC | 45.95% | 57.38% | 57.38% | ||
P1 value and P2 value represent the P values for comparisons of cancer-specific death and death from other causes with cumulative incidence function (CIF) method, respectively. Bold P values indicate that the corresponding item has statistical significance.
AJCC, American Joint Committee on Cancer; ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; NA, not available.